Efficacy and Safety of Abacavir/Lamivudine/Zidovudine Plus Tenofovir in HBV/HIV-1 Coinfected Adults: 48-Week Data

In HBV/HIV-coinfected patients, the risk of end-stage liver disease and death is increased. This open-label, prospective, pilot study evaluated abacavir/lamivudine/zidovudine twice daily plus tenofovir once daily in HBV/HIV-coinfected antiretroviral-naïve subjects. Nine adults (8 males) enrolled, wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Rodriguez, Allan E, DeJesus, Edwin, Williams, Vanessa, Irlbeck, David, Ross, Lisa, Ha, Belinda, Lancaster, Charles T
Formato: Texto
Lenguaje:English
Publicado: Bentham Open 2010
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3023942/
https://www.ncbi.nlm.nih.gov/pubmed/21253458
http://dx.doi.org/10.2174/1874613601004010167

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3023942/
https://www.ncbi.nlm.nih.gov/pubmed/21253458
http://dx.doi.org/10.2174/1874613601004010167

Ejemplares similares